Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsInterest & Investment IncomeNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Mimedx (MDXG) Cost of Revenue (2016 - 2025)

Historic Cost of Revenue for Mimedx (MDXG) over the last 16 years, with Q3 2025 value amounting to $18.7 million.

  • Mimedx's Cost of Revenue rose 2217.07% to $18.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $70.9 million, marking a year-over-year increase of 2431.5%. This contributed to the annual value of $60.1 million for FY2024, which is 995.53% up from last year.
  • As of Q3 2025, Mimedx's Cost of Revenue stood at $18.7 million, which was up 2217.07% from $18.7 million recorded in Q2 2025.
  • In the past 5 years, Mimedx's Cost of Revenue registered a high of $18.7 million during Q3 2025, and its lowest value of $7.1 million during Q4 2021.
  • For the 5-year period, Mimedx's Cost of Revenue averaged around $13.5 million, with its median value being $13.6 million (2023).
  • Per our database at Business Quant, Mimedx's Cost of Revenue crashed by 3438.11% in 2021 and then soared by 10243.73% in 2022.
  • Mimedx's Cost of Revenue (Quarter) stood at $7.1 million in 2021, then surged by 102.44% to $14.4 million in 2022, then dropped by 3.67% to $13.8 million in 2023, then increased by 22.16% to $16.9 million in 2024, then grew by 10.7% to $18.7 million in 2025.
  • Its Cost of Revenue stands at $18.7 million for Q3 2025, versus $18.7 million for Q2 2025 and $16.6 million for Q1 2025.